© Anne Schönharting
What inspired you to found your startup?
Key has been the aim to bring effective treatment to the patient – together with the strong belief that our approach will succeed, since it is based on sound understanding of the underlying scientific field.
How do you define success for yourself and your company?
The success of the company is the ability of the entire team to reach the economic and scientific aims the company was founded for.
Is there anything you’d do differently if you could do it again?
No, not really.
What problem does your product solve?
Less side effects than current treatments, putative curative effects to diseased hearts.
Where do you see your company in 1/5/10 years?
1 Year: ready to start clinical phase II
5 Years: conducted an exit for the atrial fibrillation project;
10 Years: OMEICOS 2, to be founded, develops further drugs in different indications.
How are you different?
The compounds activate bodies’ own, cardio-protective molecular pathway that stabilizes the heart’s rhythm.
How often does your product/service show up in a user’s day or week?
Once daily, oral treatment.
Impact: how are you doing good and building a better future?
Giving patients an option for a better medical treatment.
How has the startup scene in Berlin changed?
More money for startups in the biotech sector.
What are the pros and cons of launching your startup from Berlin?
There are no real cons, Berlin is the perfect place to be.
Omeicos Therapeutics was featured in “The Hundert Vol. 10 – Startups of Berlin“, October 2017.